Display Settings:

Format

Send to:

Choose Destination
    Curr Oncol Rep. 2007 Jul;9(4):241-6.

    Vaccine therapy in non-small-cell lung cancer.

    Source

    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. Albri015@mc.duke.edu

    Abstract

    Lung cancer is the leading cause of death from cancer worldwide. First-line therapy is based on stage at diagnosis and can include chemotherapy, radiation, and surgery. Despite advances, the prognosis for advanced-stage lung cancer is very poor. Vaccines with the capability to activate the host immune system may have a role in second-line therapy. Advances in the understanding of cellular and molecular immunology are forming the basis for improving vaccine therapy. Most trials to date have demonstrated safety but inconsistent efficacy. Further research is needed to enhance this potential.

    PMID:
    17588347
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk